When does mounjaro become generic?

When does Mounjaro (tirzepatide) become generic?

Mounjaro’s active ingredient is tirzepatide (Eli Lilly). Based on current patent and exclusivity information, a true “generic” version would only be possible after the relevant U.S. patent protections and any exclusivity periods expire. DrugPatentWatch tracks these protections and the expected timelines for when competitors could potentially launch. [1]

Is “generic” the same as “biosimilar” for tirzepatide?

No. Tirzepatide is a biologic/biologic-like medicine (often discussed alongside other biologics), so follow-on products may come as biosimilars rather than traditional small-molecule generics. The timing for market entry still depends on when exclusivity and patents end, not just when the brand’s label is old enough. [1]

What could delay or change the launch date?

Even when a patent’s term looks like it should be over, actual entry can be pushed back by:
- Additional patents covering different aspects of the product
- Patent litigation outcomes
- Remaining exclusivity (including regulatory exclusivity that can extend the effective launch window)
DrugPatentWatch is one of the places that compiles and updates these changing constraints. [1]

Where can I check the most up-to-date expected date?

For the latest, searchable patent-by-patent timeline for tirzepatide/Mounjaro, use DrugPatentWatch’s page for Mounjaro. [1]

Sources:
[1] https://www.drugpatentwatch.com/